uBriGene Biosciences Inc.

Pioneering Gene Therapy: #uBriGene as Your Strategic Partner uBriGene Biosciences proudly announces that our partner, #InnoVec_Biotherapeutics, has received #FDA clearance for their IND application of IVB103—an innovative #AAV_based_gene_therapy for neovascular age-related macular degeneration (nAMD). This groundbreaking therapy leverages InnoVec’s EASI-FIND® AAV discovery platform and showcases our role as a strategic partner in advancing cutting-edge drug development. At uBriGene, we are dedicated to delivering comprehensive #CDMO_services, covering everything from #plasmid_process_development (PD) and #GMP_manufacturing to AAV PD and GMP production, as well as regulatory IND filing support. We’re honored to collaborate with InnoVec and contribute to their groundbreaking work in gene therapies. Here’s to pushing the boundaries of innovation together! https://lnkd.in/ghCF3fQB

Discover how #uBriGene’s advanced #mRNA_LNP platform revolutionizes therapeutic development with unmatched efficiency and precision. https://lnkd.in/gUKnbtUe!

🚀 Discover the Basics of CAR-T Therapies! 🚀 Looking to master CAR-T therapies, from concept to GMP manufacturing? Dive into #uBriGene on-demand #educational_webinar, "CAR-T 101," and get up to speed with this groundbreaking approach to cancer treatment! 🎯 What You’ll Explore: - Key requirements for #CAR_T therapy development - Techniques for #gene_modification of T-cells - #GMP_manufacturing workflows - Regulatory considerations for #clinical use ▶ Watch now or anytime via https://lnkd.in/gFqsvNvm

9-Month FDA IND Clearance: uBriGene's Speed Redefined 🎉 We’re thrilled to celebrate a remarkable achievement with our strategic partner, #InnoVecBiotherapeutics! In just nine months, #uBriGeneBiosciences has propelled InnoVec’s IVB103—an #AAV-based gene therapy for neovascular age-related macular degeneration (nAMD)—to FDA IND clearance. This speedy milestone reflects our team's unwavering dedication and expertise in providing comprehensive CDMO services. From plasmid process development to AAV GMP manufacturing and regulatory documentation, we’re committed to fast-tracking groundbreaking therapies to clinical trials. Thank you to our incredible team and to InnoVec Biotherapeutics for this phenomenal partnership. Together, we’re advancing gene therapies at unprecedented speeds! https://lnkd.in/ghCF3fQB #CDMOServices #PlasmidProcessDevelopment #AAVGMPManufacturing #DrugDevelopment #GeneTherapy #FDAINDclearance

🚀 Transforming mRNA Therapy with Advanced Microfluidics Technology 🚀 At #uBriGene, we are redefining the landscape of mRNA therapy through our cutting-edge microfluidics technology. Our approach addresses the core challenges in mRNA development: 🔬 Stabilized mRNA: Our #microfluidic systems enable LNPs to encapsulate and protect mRNA from nuclease degradation, ensuring enhanced stability. 🎯 Targeted Delivery Systems: We engineer LNPs to deliver mRNA payloads directly into the cytoplasm, boosting the efficiency of the translational process. 🔓 Endosomal Release: Our technology facilitates the crucial escape of mRNA from endosomes, maximizing its functionality. 🛡️ Reduced Immunogenicity: Optimized mRNA constructs minimize immune responses, promoting both safety and efficacy in therapeutic applications. Discover how uBriGene is pushing the boundaries of innovation in #mRNAtherapy. Together, we’re making breakthroughs that matter. #geneediting #LNPencapsulation

🌟 Why should choose #uBriGene ‘s mRNA-LNP Platform! At uBriGene, we integrate proprietary high-efficiency #mRNA in vitro transcription (IVT) with advanced microfluidic technology to deliver unparalleled results. The mRNA-LNP we produce has the following characteristics: ✨ Consistent batch rates exceeding 90% 📦 Packaging efficiency above 80% 🎯 Controllable particle sizes (50-200nm) 🔬 mRNA products available from mg to g levels Our cutting-edge approach in mRNA synthesis and LNP encapsulation sets new standards in therapeutic development. Learn more about our innovative platform and explore the future of mRNA therapy at https://lnkd.in/gUKnbtUe #mRNA #geneediting #microfluidics #lipidnanoparticles #microfluidictechnology

🌟 Join our team at #uBriGene! 🧬 We're hiring a RA/Scientist specializing in upstream process development to drive impact in our Process Development Department. If you have hands-on experience with cell culture, small-scale bioreactors, fermenters, and molecular/cellular analysis, apply now and be part of our innovative journey! Check here for more open positions https://lnkd.in/gpHMKyE3 #ProcessDevelopment #CellAndGeneTherapy #CellCulture #Bioreactors #MolecularAnalysis #UpstreamProcess

📺 Watch uBriGene's ATMPs Webinar Recordings Now! Recordings of uBriGene's recent webinar series on Advanced Therapy Medicinal Products (ATMPs) are now available for viewing via www.ubrigene.com/webinar. These webinars cover essential topics like regulatory insights, cGMP manufacturing, and successful case studies in ATMPs. Whether you're new to the field or looking to deepen your knowledge, this series offers valuable insights and networking opportunities. 🔗 Add this page https://lnkd.in/g-3at8mQ to your Favorites to catch up at your convenience. And stay tuned for updates on upcoming webinars and additional resources from #uBriGene. #ATMPs #Biotechnology #CellTherapy #ViralVectors #mRNA #GeneTherapy #GeneEditing #CARcelltherapy

🔬 Explore #uBriGene’s forefront role in scalable Lentiviral Vector (LVV) production! uBriGene's LVV manufacturing and testing platform accelerates the development of cell therapies by offering validated cell lines and LVV helper plasmids, enabling efficient, high-quality, and large-scale vector production. This reduces time to clinical trials and navigates scientific and regulatory challenges seamlessly. Key features of uBriGene’s scalable #LVV production platforms are: 🧬 Proprietary 293TH suspension cell line for high-yield LV production, serum-free. 📈 LVV yields exceeding E8 TU/mL (using Jurkat T). 🌐 Scalable production from 50L to 2000L, accommodating projects of any size. 🔍 Advanced downstream purification methods ensure maximum efficiency, purity, and potency. Join "Lentiviral Vector Basics" live seminar this Thursday at 12:00 PM EST to delve deeper into uBriGene’s innovations! 🔗 Register now for free and secure your spot via https://lnkd.in/g-3at8mQ #CellTherapy #LentiviralVector #GeneTherapy #helperPlasmid

🧬 June 2024 Webinar on "Lentiviral Vector Basics" Educational Live Webinars hosted by uBriGene Biosciences Inc. is now available with the 2nd episode of "Lentiviral Vector Basics for Cell Therapy Applications." 🗓️ Date: June 27th, Thursday 🕛 Time: 12:00 PM EST 🎤 Presenter: Kenneth Warrington, Ph.D., Executive Director, Strategic Business Development, Head of Technical Services ℹ️ Dive deep into the fundamentals of Lentiviral Vector (LV) and their crucial role in gene-modified cell therapies. Learn about LV definition, characteristics, manufacturing approaches, scalability considerations, and strategies to accelerate deployment in cell therapy. 🔗 Register now for free and secure your spot via https://lnkd.in/g-3at8mQ Let's advance our understanding together and explore the future of cell therapy innovations! #CellTherapy #LentiviralVectors #Biotechnology #GeneTherapy #lentivirus #car_t #car_nk #cellandgenetherapy